Schizophrenia and the alpha7 nicotinic acetylcholine receptor.
about
Dynamic Network Connectivity: A new form of neuroplasticityNeuromodulation of thought: flexibilities and vulnerabilities in prefrontal cortical network synapsesNicotine addictionCircuit-based framework for understanding neurotransmitter and risk gene interactions in schizophreniaVisual perception and its impairment in schizophreniaCelecoxib Adjunctive Treatment to Antipsychotics in Schizophrenia: A Review of Randomized Clinical Add-On TrialsSmoking cessation and reduction in people with chronic mental illnessBrain Functional Effects of Psychopharmacological Treatments in Schizophrenia: A Network-based Functional Perspective Beyond Neurotransmitter SystemsContribution of NMDA receptors to dorsolateral prefrontal cortical networks in primatesα7 nicotinic ACh receptors as a ligand-gated source of Ca(2+) ions: the search for a Ca(2+) optimumCholinergic modulation of the medial prefrontal cortex: the role of nicotinic receptors in attention and regulation of neuronal activitySensory disturbances, inhibitory deficits, and the P50 wave in schizophreniaDrug elucidation: invertebrate genetics sheds new light on the molecular targets of CNS drugs.Targeting Prefrontal Cortical Systems for Drug Development: Potential Therapies for Cognitive DisordersNicotinic α7 receptors enhance NMDA cognitive circuits in dorsolateral prefrontal cortexA genome-wide RNAi screen in Caenorhabditis elegans identifies the nicotinic acetylcholine receptor subunit ACR-7 as an antipsychotic drug targetCigarette smoking and cognitive function in Chinese male schizophrenia: a case-control studyMaximizing the effect of an α7 nicotinic receptor PAM in a mouse model of schizophrenia-like sensory inhibition deficits.Glutamatergic synaptic dysregulation in schizophrenia: therapeutic implications.Long-term improvements in sensory inhibition with gestational choline supplementation linked to α7 nicotinic receptors through studies in Chrna7 null mutation mice.Evaluation of nicotine and cotinine analogs as potential neuroprotective agents for Alzheimer's disease.Cellular, molecular, and genetic substrates underlying the impact of nicotine on learning.Nicotine effect on prepulse inhibition and prepulse facilitation in schizophrenia patientsEvaluating the role of the alpha-7 nicotinic acetylcholine receptor in the pathophysiology and treatment of schizophrenia.Arousal and attention re-orienting in autism spectrum disorders: evidence from auditory event-related potentials.Perception of smoking risks and motivation to quit among nontreatment-seeking smokers with and without schizophreniaNicotine ameliorates NMDA receptor antagonist-induced deficits in contextual fear conditioning through high-affinity nicotinic acetylcholine receptors in the hippocampus.Beyond the dopamine receptor: novel therapeutic targets for treating schizophrenia.Cognitive effects of nicotine: genetic moderators.Schizophrenia from a neural circuitry perspective: advancing toward rational pharmacological therapiesLack of beneficial galantamine effect for smoking behavior: a double-blind randomized trial in people with schizophrenia.Fluctuations in endogenous kynurenic acid control hippocampal glutamate and memoryPhysiological concentrations of choline activate native alpha7-containing nicotinic acetylcholine receptors in the presence of PNU-120596 [1-(5-chloro-2,4-dimethoxyphenyl)-3-(5-methylisoxazol-3-yl)-urea].Cortical kynurenine pathway metabolism: a novel target for cognitive enhancement in Schizophrenia.Proteomic analysis of an alpha7 nicotinic acetylcholine receptor interactome.Pharmacology of nicotine: addiction, smoking-induced disease, and therapeuticsChemistry and pharmacological characterization of novel nitrogen analogues of AMOP-H-OH (Sazetidine-A, 6-[5-(azetidin-2-ylmethoxy)pyridin-3-yl]hex-5-yn-1-ol) as α4β2-nicotinic acetylcholine receptor-selective partial agonists.Atypical antipsychotics as noncompetitive inhibitors of alpha4beta2 and alpha7 neuronal nicotinic receptorsSchizophrenia drug discovery and development in an evolving era: are new drug targets fulfilling expectations?Tobacco craving in smokers with and without schizophrenia.
P2860
Q24597628-0E63996D-8CF5-41EA-8416-A1ABAC1F6EBFQ24619549-CAFE4A02-EDE8-49A4-8203-15F61078694BQ24626554-AF2EEB88-5E53-44D4-8F0F-4933DF09743DQ24646206-3B86C646-F4E8-477E-A190-6044C949C6E3Q24651844-314AAF61-2514-4896-B2B8-D6FD0EA7D42FQ26741541-66F190B3-AF08-4628-B013-84607F3BC251Q26782639-B3B79CFA-29FF-447B-A3B2-7272496C7636Q26786247-44522603-94B8-4943-8A54-971812950B67Q26820417-223E22B3-DB74-4D17-AB2A-1912E7600CF5Q26852967-D5B52170-5FC9-4CD8-9612-EDBA64E3F305Q26991451-7C3C6C7D-63FD-4AD2-B672-476C02EBF8EDQ27026737-96EF8C98-841F-4165-AB33-A09EF4D8617CQ27693888-58F72215-20E3-47C2-AF55-246167A182FFQ28076907-B656EC0F-F5BF-463E-B159-FBAAC9E841F9Q28293779-3E8E8AD4-5ACB-4FFB-868F-C31F952B2FD6Q28487183-E6EDCEC2-1559-4F4A-B5FF-57F2A04C61AAQ28730147-9C5569CF-559E-4777-AFDA-76C5A521E858Q30381001-DF9C2839-02AD-4160-99D9-2942DA1F367CQ30387014-510797C4-818D-453F-912B-0356D1C91A68Q30413798-CD214104-0938-42C0-85B1-FC71419C4BF8Q30416730-B3E8FA5B-381E-426C-B588-7F0D1326996FQ30422037-32DD0BA0-451C-4272-BF5C-FCED318B136BQ30425458-A13B8C50-21B3-4FA3-A1F3-71AC0A5BA893Q30428422-A7304A29-7ED5-4660-9B0D-75CC8A23F00FQ30442728-2A95552F-76AD-4B1F-AA0F-8B7885C02460Q30455113-919057DB-B7FD-4564-BFE5-A85422ABCCFDQ30470074-E51FDAE2-19E0-488E-AC9E-645D69440438Q30473410-A9E85FBD-2EC2-405E-AA51-0E023EE6015AQ30474904-7A890A42-A021-49D1-8879-1372B825F6BBQ30484459-26CD2EBC-B874-465F-A9FB-BC10B4C92CE3Q30487876-C03208C8-B055-4AAE-B9AB-BEECD7896647Q30504501-A58AF25B-B405-4FB4-ACC9-434EB49EFA98Q33613585-382E29A9-C785-4394-A26E-0582D6811EDDQ33707711-55524E09-8EFA-4B93-AC77-9115EBEB67F7Q33938764-8C6ED750-4E32-4075-9FBA-9E8DF85BE43CQ34157674-FFA97B46-AE75-452A-88AC-6C1F231A2795Q34215376-820F7F11-2610-4572-BDF7-3BB0275951D8Q34394895-F57BB939-99F8-4260-8556-C165B187E15BQ34458090-ED9547A0-32B5-4897-810F-11C9C117BC2BQ34634287-7887AF17-6645-4B8F-A952-A68C3B700E7D
P2860
Schizophrenia and the alpha7 nicotinic acetylcholine receptor.
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Schizophrenia and the alpha7 nicotinic acetylcholine receptor.
@ast
Schizophrenia and the alpha7 nicotinic acetylcholine receptor.
@en
Schizophrenia and the alpha7 nicotinic acetylcholine receptor.
@nl
type
label
Schizophrenia and the alpha7 nicotinic acetylcholine receptor.
@ast
Schizophrenia and the alpha7 nicotinic acetylcholine receptor.
@en
Schizophrenia and the alpha7 nicotinic acetylcholine receptor.
@nl
prefLabel
Schizophrenia and the alpha7 nicotinic acetylcholine receptor.
@ast
Schizophrenia and the alpha7 nicotinic acetylcholine receptor.
@en
Schizophrenia and the alpha7 nicotinic acetylcholine receptor.
@nl
P1476
Schizophrenia and the alpha7 nicotinic acetylcholine receptor.
@en
P2093
Laura F Martin
Robert Freedman
P304
P356
10.1016/S0074-7742(06)78008-4
P577
2007-01-01T00:00:00Z